Anastrozole Tablet, Coated
Product Images NDC 68382-209

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68382-209). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 01

Chemical structure of Anastrozole depicted as a molecular diagram showing the arrangement of atoms and bonds for the active ingredient in Anastrozole tablets.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 02

A Kaplan-Meier curve chart comparing disease-free survival over months for patients treated with anastrozole versus tamoxifen. The x-axis represents disease-free survival in months up to 90 months, and the y-axis shows the proportion of patients alive and disease-free ranging from 0 to 1. Two lines indicate randomized treatment groups for anastrozole (dashed line) and tamoxifen (solid line). A risk table below shows the number of patients at risk at various time points for each treatment group.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 03

A line graph depicting disease-free survival over 90 months comparing two treatments: anastrozole (dashed line) and tamoxifen (solid line). The y-axis shows the proportion of patients alive and disease-free, while the x-axis represents disease-free survival in months. The graph includes numbers of patients at risk for each treatment at various time points.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 04

Kaplan-Meier survival curve showing the proportion event-free over time (months) for patients treated with Anastrozole versus Tamoxifen. The x-axis represents time to event in months up to 120 months, and the y-axis shows the proportion event free from 0.50 to 1.00. The number of patients at risk is listed below the x-axis for both treatments at specified time points.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 05

A Kaplan-Meier curve chart depicting time to event in months for patients treated with Anastrozole versus Tamoxifen. The y-axis shows the proportion event free, and the x-axis shows time up to 120 months. Below the x-axis is a table listing the number of patients at risk for both treatment groups at various time points.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 06

A progression-free survival curve comparing randomized treatments with Anastrozole and Tamoxifen over time to progression in months. The y-axis shows the proportion not progressing, and the x-axis shows time in months, with a table indicating the number of patients at risk at each time point for both treatments.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 07

A line chart comparing the proportion not progressing over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, ranging from 0 to 42. The y-axis shows the proportion not progressing, from 0.0 to 1.0. The graph includes a table of patients at risk at various time points.*

FDA Label Image

A4544840 7708 43a7 95ec 7482241e67a3 08

Anastrozole Tablets, USP 1 mg coated tablets in a bulk package containing 1,000 tablets. The label includes usage and storage instructions, pharmacist dispensing information, and warnings about child resistance. Manufactured by Cadila Healthcare Ltd. and distributed by Zydus Pharmaceuticals USA Inc. The package is marked for prescription use only and includes the NDC 68382-209-10.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.